Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 5/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773551 | 0.85 | MAPK14 (0.49) | MAPK14CSNK1D | |
| SCHEMBL5774665 | 0.82 | MAPK14 (0.60) | MAPK14TGFBR1 | |
| SCHEMBL5773894 | 0.76 | MAPK14 (0.62) | MAPK14 | |
| SCHEMBL6185443 | 0.74 | MAPK14 (0.53) | MAPK14CSNK1DCSNK1E | |
| SCHEMBL5837490 | 0.72 | MAPK14 (0.65) | MAPK14CSNK1DCSNK1E | |
| SCHEMBL5836670 | 0.72 | MAPK14 (0.60) | MAPK14CSNK1DCSNK1E | |
| SCHEMBL5776532 | 0.71 | MAPK14 (0.54) | MAPK14CSNK1DCSNK1ETGFBR1 | |
| SCHEMBL5773898 | 0.71 | MAPK14 (0.56) | MAPK14CSNK1DTGFBR1 | |
| SCHEMBL5772729 | 0.69 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL5836709 | 0.69 | MAPK14 (0.65) | MAPK14CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370559-B1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | PFIZER PROD INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6696464-B2 | POTENT INHIBITORS OF MAP KINASES, PREFERABLY P38 KINASE; USEFUL IN TREATMENT OF INFLAMMATION, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, REPERFUSION OR ISCHEMIA IN STROKE OR HEART ATTACK | PFIZER INC | 2004-02-24 | — | — | US | disclosed |
| EP-1370559-A1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | Pfizer Products Inc. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030096838-A1 | Novel triazolo-pyridines anti-inflammatory compounds | PFIZER INC. | 2003-05-22 | — | — | US | disclosed |
| WO-2002072579-A1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | PFIZER PRODUCTS INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096838-A1 | Novel triazolo-pyridines anti-inflammatory compounds | MAPK1, CNKSR1, JAK1 | MAPK14 15/4885CSNK1D 590/4885CSNK1E 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.